Trials / Completed
CompletedNCT02342379
TH-302 in Combination With Bevacizumab for Glioblastoma
A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | 10mg/kg |
| DRUG | TH-302 | 670mg/m2 |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2019-01-04
- Completion
- 2019-12-04
- First posted
- 2015-01-19
- Last updated
- 2020-04-10
- Results posted
- 2020-04-10
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02342379. Inclusion in this directory is not an endorsement.